Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines.

ABSTRACT: Tissue engineering strategies predominantly rely on the production of living substitutes, whereby implanted cells actively participate in the regenerative process. Beyond cost and delayed graft availability, the patient-specific performance of engineered tissues poses serious concerns on their clinical translation ability. A more exciting paradigm consists in exploiting cell-laid, engineered extracellular matrices (eECMs), which can be used as off-the-shelf materials. Here, the regenerative capacity solely relies on the preservation of the eECM structure and embedded signals to instruct an endogenous repair. We recently described the possibility to exploit custom human stem cell lines for eECM manufacturing. In addition to the conferred standardization, the availability of such cell lines

SUBMITTER: Prithiviraj S 

PROVIDER: S-EPMC11952750 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature